User:Mr. Ibrahem/Teclistamab

Teclistamab, sold under the brand name Tecvayli, is a medication used to treat multiple myeloma. It is used when other treatments have failed. It is given by injection under the skin.

Common side effects include fever, cytokine release syndrome, muscle pain, tiredness, upper respiratory tract infection, pneumonia, diarrhea, low white blood cells, low red blood cells, and low platelets. Other side effects may include liver problems, infection, and allergic reactions. Use in pregnancy may harm the baby. It is amonoclonal antibody that simultaneously attaches to the CD3 receptors on T-cells and the B-cell maturation antigen (BCMA) myeloma cells.

Teclistamab was approved for medical use in Europe and United States in 2022. In the United States it costs about 40,000 USD per month as of 2022. It is not approved in the United Kingdom as of 2022.